Address Hotels and Resorts Announces the Opening of Address Jabal Omar Makkah Unveiling a Spiritual Haven in the Heart of Makkah
12.7.2023 09:00:00 EEST | Business Wire | Press release
Address Hotels and Resorts is thrilled to announce the opening of its latest architectural and hospitality masterpiece, Address Jabal Omar Makkah, in the holy city of Makkah, Saudi Arabia. Nestled in the iconic Jabal Omar development, this landmark property offers a truly unforgettable experience for pilgrims and travellers alike.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230711493267/en/
Panoramic Kaaba view from Address Jabal Omar Makkah (Photo: AETOSWire)
The largest hotel within the Address Hotels and Resorts portfolio, Address Jabal Omar Makkah boasts an impressive 1,484 rooms and suites. With its striking architectural design, a seamless fusion of ancient Arabian charm and contemporary opulence, the hotel is the tallest building in Jabal Omar and is a breathtaking sight.
One standout feature of Address Jabal Omar Makkah is its proximity to the sacred Holy Kaaba and Al Masjid Al Haram, along with the Makkah Museum, Masjid Al Jinn, Jannat al-Mu'alla Cemetery, and the iconic Abraj Al Bait Towers. Designed by the world-renowned architects Foster & Partners, the towers of Address Jabal Omar Makkah span over 5,000 sqm and the development includes a commercial area featuring a diverse range of shops, showcasing local, regional, and international brands.
Address Jabal Omar Makkah offers a range of exquisitely designed accommodations to suit every traveller’s needs. From luxurious Deluxe Rooms, which provide splendid views of the Holy Kaaba or the Holy City, to indulgent Suites and the magnificent three-bedroom Presidential Suite and four-bedroom Penthouse, guests can immerse themselves in comfort and elegance.
With four restaurants, two lobby lounges, and two club lounges, guests can also savour a wide range of delectable cuisines. The hotel's signature dining venue offers traditional Hejazi cuisine and other Saudi Arabian specialties, where live cooking stations showcase international flavours alongside time-honoured delicacies.
The spa and wellness offerings, including the first-ever Foot Spa by Address Hotels and Resorts, at the hotel are designed to provide guests with a truly holistic experience. With a complimentary Fitness Centre, equipped with the latest Technogym equipment on hand as well, guests can maintain their well-being during their stay.
Address Jabal Omar Makkah is also a premier destination for conferences and events. Whatever the occasion, the hotel’s unparalleled settings and services help create cherished moments. The property's multifunctional meeting spaces are designed to cater to events of any scale. The hotel's creative chefs curate menus tailored to individual preferences, ensuring a flawless and memorable event.
Mark Kirby, Head of Emaar Hospitality, said, “We are delighted to announce the opening of Address Jabal Omar Makkah. Its prime location makes it the preferred choice for those seeking to deepen their spiritual connection. With spacious rooms and suites, multiple dining options, and state-of-the-art prayer facilities, the hotel offers all the amenities necessary for a meaningful and unforgettable pilgrimage experience. Whether guests are here for Hajj, Umrah, or to enhance their spiritual connection, Address Jabal Omar Makkah Hotel is the optimal starting point for their journey.”
The hotel is proud to be a part of Saudi Arabia's Vision 2030, which aims to transform the country's tourism landscape.
To reserve with a 15% discount, click the link, visit our website, or email stayatmakkah@addresshotels.com or call +966-0125531444.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230711493267/en/
Contact information
Mohammad Jamil
Mohammad.j@addresshotels.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release
The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 14:24:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: "While the median age of diagnosis for CLL is 70 and the average age of treatment initiation is 75, many pivotal trials still underrepresent the patients that physicians most often see in practice. These data show that the durable benefit of
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 14:00:00 EEST | Press release
Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction. GreensLedge Capital Markets advised the seller. About Clearlake Clearlake Capital is a leading global alternative a
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 14:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified. Perspectives on head-to-head zasocitinib study “In this head-to-head study, zasocitinib clearly demonstrated
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 13:30:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reliability, operational efficiency and sustainability performance. The partnership brings together LTTS’ expertise in forward looking technologies and extensive experience ac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom